Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapies designed to guide and reprogram T cells to overcome autoimmunity, inflammatory disease, chronic viral infection, and cancer. - View it on GitHub